June 2020
Volume 61, Issue 7
Free
ARVO Annual Meeting Abstract  |   June 2020
Alu RNA exacerbates experimental choroidal neovascularization via an inflammasome-dependent pathway
Author Affiliations & Notes
  • Felipe Pereira
    Ophthalmology, University of Virginia, Charlottesville, Virginia, United States
  • Ivana Apicella
    Ophthalmology, University of Virginia, Charlottesville, Virginia, United States
  • Ryan Makin
    Ophthalmology, University of Virginia, Charlottesville, Virginia, United States
  • Younghee Kim
    University of Kentucky, Kentucky, United States
  • Charles Wright
    University of Kentucky, Kentucky, United States
  • Tetsuhiro Yasuma
    University of Kentucky, Kentucky, United States
  • Reo Yasuma
    University of Kentucky, Kentucky, United States
  • Shuichiro Hirahara
    Ophthalmology, University of Virginia, Charlottesville, Virginia, United States
  • Shinichi Fukuda
    Ophthalmology, University of Virginia, Charlottesville, Virginia, United States
  • Siddharth Narendran
    Ophthalmology, University of Virginia, Charlottesville, Virginia, United States
  • Romulo Albuquerque
    University of Kentucky, Kentucky, United States
  • Benjamin Fowler
    University of Kentucky, Kentucky, United States
  • Nagaraj Kerur
    Ophthalmology, University of Virginia, Charlottesville, Virginia, United States
  • Jayakrishna Ambati
    Ophthalmology, University of Virginia, Charlottesville, Virginia, United States
  • Bradley Gelfand
    Ophthalmology, University of Virginia, Charlottesville, Virginia, United States
  • Footnotes
    Commercial Relationships   Felipe Pereira, None; Ivana Apicella, None; Ryan Makin, None; Younghee Kim, None; Charles Wright, None; Tetsuhiro Yasuma, None; Reo Yasuma, None; Shuichiro Hirahara, None; Shinichi Fukuda, None; Siddharth Narendran, None; Romulo Albuquerque, None; Benjamin Fowler, None; Nagaraj Kerur, University of Virginia (P); Jayakrishna Ambati, Allergan (C), Allergan (R), Immunovant (C), Inflammasome Therapeutics (I), Inflammasome Therapeutics (S), Inflammasome Therapeutics (P), iVeena Delivery Systems (I), iVeena Delivery Systems (S), iVeena Holdings (I), iVeena Holdings (S), Olix Pharmaceuticals (C), Retinal Solutions (C), Saksin LifeSciences (C), Saksin LifeSciences (R); Bradley Gelfand, None
  • Footnotes
    Support  none
Investigative Ophthalmology & Visual Science June 2020, Vol.61, 5394. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Felipe Pereira, Ivana Apicella, Ryan Makin, Younghee Kim, Charles Wright, Tetsuhiro Yasuma, Reo Yasuma, Shuichiro Hirahara, Shinichi Fukuda, Siddharth Narendran, Romulo Albuquerque, Benjamin Fowler, Nagaraj Kerur, Jayakrishna Ambati, Bradley Gelfand; Alu RNA exacerbates experimental choroidal neovascularization via an inflammasome-dependent pathway. Invest. Ophthalmol. Vis. Sci. 2020;61(7):5394.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : Alu RNA is a long non-coding RNA implicated in atrophic macular degeneration. Alu RNA induces RPE death via activation of the inflammasome. The purpose of this study is to determine the role of Alu RNA and inflammasome in aberrant angiogenesis using an experimental choroidal neovascularization (CNV) model.

Methods : CNV was induced by laser photocoagulation in C57BL/6J wild-type mice, or mice lacking molecular constituents of inflammasome (P2rx7–/–, Nlrp3–/–, caspase1–/–/11–/–, and Myd88–/– mice). Alu RNA or vehicle was administered by subretinal injection immediately after and adjacent to the laser injury. Intravitreous injections of inhibitors P2xr7, caspase 1, or MyD88 in wild-type mice were performed following laser injury and Alu RNA injection. CNV volume was measured after 7 days by confocal microscopy. qRT-PCR and ELISA of vascular endothelial growth factor (VEGF) were performed in mouse bone marrow-derived cells and human retinal pigment epithelial cells transfected with Alu RNA.

Results : Alu RNA amplified the choroidal angiogenic response in response to laser injury in wild type mice but not in P2rx7–/–, Nlrp3–/–, caspase1–/–/11–/–, or Myd88–/– mice (P<0.05). Pharmacologic inhibition of P2xr7, caspase 1, or MyD88 in wild-type mice reduced the angiostimulatory effect of Alu RNA on laser CNV (P<0.05). In cells, Alu RNA stimulation increased mRNA expression and secretion of VEGF (P<0.05).

Conclusions : Alu RNA is capable of significantly increase VEGF release in-vitro and exacerbate experimental CNV. Genetic or pharmacologically inhibition of different inflammasome mediators were able to abrogate this Alu RNA activity. Thus, in addition to promoting RPE atrophy, Alu RNA-induced inflammasome activation may contribute to aberrant angiogenesis.

This is a 2020 ARVO Annual Meeting abstract.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×